Validation of a chloroquine-induced cell death mechanism for clinical use against malaria

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Ch'ng, J H ^a,b   Lee, Y Q ^a,c   Gun, S Y ^d   Chia, W N ^d   Chang, Z W ^d   Wong, L K ^a   Batty, K T ^e,f   Russell, B ^a   Nosten, F ^g,h   Renia, L ^d   Tan, K S W ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

^e CURTIN UNIVERSITY   (Australia)

^f West Coast Institute   (Australia)

^g MAHIDOL UNIVERSITY   (Thailand)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; ANTIMALARIAL AGENT; HEMOPROTEIN; HEMOZOIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL PERMEABILIZATION; CONTROLLED STUDY; CYTOPLASM; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEASIBILITY STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITE VIABILITY; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; RODENT MALARIA; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DRUG SCREENING; MALARIA; METABOLISM; PLASMODIUM;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION; HEMEPROTEINS; MALARIA; MICE; MICE, INBRED BALB C; PLASMODIUM;

EID: 84903766653     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.265     Document Type: Article

References (29)

1. The malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med 2011; 8: e1000402.
2. Yeung BK, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY et al. Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem 2010; 53: 5155-5164.
3. Burrows JN, Burlot E, Campo B, Cherbuin S, Jeanneret S, Leroy D et al. Antimalarial drug discovery-the path towards eradication. Parasitology 2013; 17: 1-12.
4. Ch'ng JH, Mok S, Bozdech Z, Lear MJ, Boudhar A, Russell B et al. A whole cell pathway screen reveals seven novel chemosensitizers to combat chloroquine resistant malaria. Sci Rep 2013; 3: 1734.
5. Ch'ng JH, Kotturi SR, Chong AG, Lear MJ, Tan KS. A programmed cell death pathway in the malaria parasite Plasmodium falciparum has general features of mammalian apoptosis but is mediated by clan CA cysteine proteases. Cell Death Dis 2010; 1: e26.
6. Ch'ng JH, Liew K, Goh AS, Sidhartha E, Tan KS. Drug-induced permeabilization of parasite's digestive vacuole is a key trigger of programmed cell death in Plasmodium falciparum. Cell Death Dis 2011; 2: e216.
7. Ch'ng JH, Renia L, Nosten F, Tan KS. Can we teach an old drug new tricks? Trends Parasitol 2012; 28: 220-224.
8. Macomber PB, O'Brien RL, Hahn FE. Chloroquine: physiological basis of drug resistance in Plasmodium berghei. Science 1966; 152: 1374-1375.
9. Zhang Y, Hempelmann E. Lysis of malarial parasites and erythrocytes by ferriprotoporphyrin IX-chloroquine and the inhibition of this effect by proteins. Biochem Pharmacol 1987; 36: 1267-1273.
10. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA 2002; 99: 990-995.
11. Rosenthal PJ. Falcipains and other cysteine proteases of malaria parasites. Adv Exp Med Biol 2011; 712: 30-48.
12. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 1996; 31: 257-274.
13. Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther 1998; 79: 55-87.
14. Yayon A, Vande Waa JA, Yayon M, Geary TG, Jensen JB. Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro. J Protozool 1983; 30: 642-647.
15. Warhurst DC, Killick-Kendrick R. Spontaneous resistance to chloroquine in a strain of rodent malaria (Plasmodium berghei yoelii). Nature 1967; 213: 1048-1049.
16. Warhurst DC, Hockley DJ. Mode of action of chloroquine on Plasmodium berghei and P. cynomolgi. Nature 1967; 214: 935-936.
17. Macomber PB, Sprinz H. Morphological effects of chloroquine on Plasmodium berghei in mice. Nature 1967; 214: 937-939.
18. Rombo L, Ericsson O, Alvan G, Lindstrom B, Gustafsson LL, Sjoqvist F. Chloroquine and desethylchloroquine in plasma, serum, and whole blood: problems in assay and handling of samples. Ther Drug Monit 1985; 7: 211-215.
19. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996; 30: 263-299.
20. Cambie G, Verdier F, Gaudebout C, Clavier F, Ginsburg H. The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy. Parasite 1994; 1: 219-226.
21. Moore BR, Page-Sharp M, Stoney JR, Ilett KF, Jago JD, KT. Batty. Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother 2011; 55: 3899-3907.
22. White NJ, Miller KD, Churchill FC, Berry C, Brown J, Williams SB et al. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med 1988; 319: 1493-1500.
23. Ursing J, Kofoed PE, Rodrigues A, Bergqvist Y, Rombo L. Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau. Antimicrob Agents Chemother 2009; 53: 180-185.
24. Ursing J, Kofoed PE, Rodrigues A, Blessborn D, Thoft-Nielsen R, Bjorkman A et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis 2011; 203: 109-116.
25. Pussard E, Lepers JP, Clavier F, Raharimalala L, Le Bras J, Frisk-Holmberg M et al. Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 1991; 35: 406-409.
26. Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA. Model system to define pharmacokinetic requirements for antimalarial drug efficacy. Sci Transl Med 2013; 5: 205ra135.
27. Malleret B, Claser C, Ong AS, Suwanarusk R, Sriprawat K, Howland SW et al. A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. Sci Rep 2011; 1: 118.
28. Spadafora C, Gerena L, Kopydlowski KM. Comparison of the in vitro invasive capabilities of Plasmodium falciparum schizonts isolated by Percoll gradient or using magnetic based separation. Malar J 2011; 10: 55.
29. Ecker A, Lakshmanan V, Sinnis P, Coppens I, Fidock DA. Evidence that mutant PfCRT facilitates the transmission to mosquitoes of chloroquine-treated Plasmodium gametocytes. J Infect Dis 2011; 203: 228-236.